# Bruce W. Robinson

Bruce William Stanley Robinson (born 2 June 1950) is an Australian pulmonary physician and cancer immunologist. He has been a consultant physician at Sir Charles Gairdner Hospital since 1984 and a Professor of Medicine at the University of Western Australia since 1995. In 2013, he was named Western Australian of the Year and was made a Member of the Order of Australia for his contributions to cancer research, particularly mesothelioma discoveries, as well as his work on The Fathering Project.

## Education

Robinson earned his medical degree from the University of Western Australia in 1974. Subsequently, he received postgraduate medical training in the United Kingdom, where he became a Fellow of the Royal College of Physicians, then received doctoral research training at the National Institute of Health in Maryland.

## Career

Robinson is the co-founder and former director of the National Center for Asbestos Related Diseases. He has published 250 scientific papers, 40 invited book chapters and invited reviews in the New England Journal of Medicine, Nature Reviews, PNAS and The Lancet and also published scientific books and continues as principal investigator on projects studying immune responses against cancer mutations and vaccines derived from such mutations.
Robinson has delivered parenting lectures focused on fathering to more than 16,000 fathers and father figures in schools, workplaces, and community organizations. He founded The Fathering Project in 2013 which seeks to increase the level of engagement between children and their fathers or father figures with a view to reducing the children's risks of substance abuse and depression.

## Research

Robinson uses computer modelling to forecast the effect of silent mutations on the immune-stimulating potential of neo-antigens, and he intends to utilise his proven animal model system to see if these novel sorts of neo-antigens are useful as cancer vaccine targets.
He addressed a problem in cancer treatment: the immune system's failure to recognise cancer cells as a threat. He also shed light on why the immune system, which is capable of recognising cancer mutations, often refrains from fighting tumour cells.

## Selected publications

* Robinson, Bruce W.S.; Lake, Richard A. (13 October 2005). "Advances in Malignant Mesothelioma". New England Journal of Medicine. 353 (15): 1591–1603. doi:10.1056/NEJMra050152. PMID 16221782.
* Robinson, Bruce W.S.; Lake, Richard A. (May 2005). "Immunotherapy and chemotherapy — a practical partnership". Nature Reviews Cancer. 5 (5): 397–405. doi:10.1038/nrc1613. PMID 15864281. S2CID 23526534.
* Robinson, Bruce W. S.; Dick, Ian M.; Creaney, Jenette; Redwood, Alec J. (31 December 2022). "What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination". OncoImmunology. 11 (1). doi:10.1080/2162402X.2022.2038403. PMC 8855878. PMID 35186441.
* Addala, Venkateswar.; Newell, Felicity; Pearson, John V.; Redwood, Alec; Robinson, Bruce W; Creaney, Jenette; Waddell, Nicola (31 October 2023). "Computational immunogenomic approaches to predict response to cancer immunotherapies". Nature Reviews Clinical Oncology. 21 (1): 28–46. doi:10.1038/s41571-023-00830-6. PMID 37907723.